drugset
drugset / Trial / NCT02244489

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

NCT02244489 ↗

Phase 1 Terminated 16 enrolled Sierra Oncology LLC - a GSK company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma.

Timeline

Start
2014-11-05
Primary completion
2017-03-08
Completion
2017-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule — Oral
Subject Momelotinib Small molecule — Oral
Subject Oxaliplatin Small molecule — Intravenous

Indications

No indication recorded.